Double-Blind Placebo-Controlled Trial of Quetiapine in Anorexia Nervosa.
About this resource
Objective: Our objective is to determine whether quetiapine was superior to placebo in increasing weight or reducing core symptoms of anorexia nervosa as assessed by the Yale–Brown–Cornell Eating Disorder Scale and the Eating Disorder Inventory-2. Method: Participants were randomised to 8 weeks of quetiapine or placebo. Results: There are 21 participants who signed informed consent, 15 were randomised, 14 returned for at least one visit after receiving drug and 10 completed the study. There were no differences between drug and placebo in questionnaire scores, weight or measures of anxiety or depression. Discussion: There was no difference between quetiapine and placebo on weight gain or core symptoms. Small effect sizes suggest that a higher number of participants would not increase significant differences between groups. Copyright © 2012 John Wiley & Sons, Ltd and Eating Disorders Association.
Cognitive Behavior Therapy for the Eating Disorders.
Cognitive behavioral therapy (CBT) is an evidence-based treatment for bulimia nervosa and binge-eating disorder and is regarded as the first-line treatment for both eating disorders.Read more
Evaluating the quality of websites relating to diet and eating disorders
OBJECTIVE: To verify whether the Credibility Indicator is able to evaluate the quality of websites.Read more
Social anxiety in the eating disorders: a systematic review and meta-analysis.
Social anxiety disorder is one of the most common comorbid conditions in eating disorders (EDs).Read more
Heightened fear of uncertainty in anorexia and bulimia nervosa
OBJECTIVE: To test whether intolerance of uncertainty (IU) is related to eating disorder (ED) pathology.Read more